Literature DB >> 33752454

Intravitreal injections during COVID-19 outbreak: Protective measures, total duration of care and perceived quality of care in a tertiary retina center.

Paul Denys1, Alexandra Miere1, Donato Colantuono1, Camille Jung2, Eric H Souied1.   

Abstract

PURPOSE: To assess patient satisfaction regarding the sudden reorganization of care during the COVID-19 pandemic in the outpatient intravitreal injection (IVI) clinic.
METHODS: A survey of patients with ongoing IVIs for retinal diseases was carried out between April 23rd and May 12th, 2020. We designed a questionnaire to assess patient satisfaction concerning: personal protective equipment (PPE), social distancing, the perceived quality of care, and the total time spent in the department, using a Likert scale. We also collected the time spent per patients in the outpatient IVI clinic.
RESULTS: A hundred and twenty-seven eyes of 108 patients were included. The mean time spent in the IVI outpatient clinic was 31.87 +/- 16.61 min. In our survey, 99.1% of the patients were satisfied (highly satisfied or satisfied) with the new type of care provided, 89.8% with the duration of care, and 93.5% with the PPE. Satisfaction was associated with total time spent in hospital (p = 0.005), with dissatisfied patients spending about 50% more time in the hospital than satisfied patients (43.91 min vs 30.50 min).
CONCLUSION: Despite the crisis-related adjustment, our survey revealed high patient satisfaction with PPE, quality of care, and total time spent in outpatient IVI clinic.

Entities:  

Keywords:  COVID-19; Intravitreal injections; age-related macular degeneration; diabetic macular edema; patient satisfaction; treatment burden

Mesh:

Year:  2021        PMID: 33752454      PMCID: PMC7992096          DOI: 10.1177/11206721211003488

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  1 in total

1.  Therapeutic effect of simultaneous intravitreal dexamethasone and aflibercept on diabetic macular edema.

Authors:  Tai-Chi Lin; Yu-Chien Chung; Tsui-Kang Hsu; Hsin-Wei Huang; Yi-Ming Huang; Yi-Chang Chou; Chen-Yu Chao; Po-Chen Tseng
Journal:  Acta Diabetol       Date:  2021-11-16       Impact factor: 4.087

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.